Group One Trading
RAPP

Group One Trading’s Rapport Therapeutics RAPP Stock Holding History

Group One Trading’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,475
Closed -$68.5K – 9364
2025
Q3 		$73.5K Buy
+2,475
New +$44.2K ﹤0.01% 5622

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Group One Trading's RAPP Position: Q4 2025 in Review

Group One Trading sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 2,475 shares — an estimated $68.5K sold.

Group One Trading first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $73.5K in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Group One Trading reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 2,475 Rapport Therapeutics shares in Q4 2025, an estimated $68.5K.
  • Group One Trading first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
  • Group One Trading's Rapport Therapeutics position peaked at $73.5K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.